Entera Bio Ltd.

NASDAQ:ENTX

Biotechnology

Healthcare
$3.26 +0.00%

+$0.00 today

Market cap
$567.69M
Beta
1.49
P/E (TTM)
-4.6
EPS (TTM)
-$0.26
52W Low $0.91High $3.22

Volume 0.49M

Average 0.16M

ENTX Accounts Receivables

Cash effect of the change in amounts owed by customers; growing receivables consume cash.

Entera Bio Ltd.NASDAQ: ENTX

Accounts Receivables · Q1 FY2026 · quarter ended Mar 2026

Accounts receivables outflow grows to $0

Q1 FY2026 accounts receivables was $0, compared with $0 a year earlier. Trailing-twelve-month accounts receivables was $133.03K.

Context

  • Accounts receivables amounted to 300.0% of revenue in FY2025, up 230.4 pp from a year earlier.
  • Accounts receivables increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly accounts receivables holds near $0 or moves back toward the trailing-twelve-month quarterly average of $33.26K.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$0-100.0% QoQ
Last fiscal yearDec 2025
$126K+200.0% YoY
LTMMar 2026
$133.03K+205.6% YoY
Accounts Receivables past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year+200.0%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Accounts Receivables history

USD · from the cash flow

Latest · FY2025
126K USD
Year-over-year change
+200.0%
4-year CAGR
+15.0%

Accounts Receivables vs competitors

How ENTX compares with its peers on the latest reported figures

  • ENTX's LTM Mar 2026 accounts receivables of $133.03K is the 7th largest of the 10 companies compared; the peer median is $331.65K.
  • Its year-over-year change of +205.6% is the 2nd highest of 8, against a peer median of -73.3%.
ENTX Competitors Peer median
Accounts Receivables for ENTX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
AGENAgenus Inc.LTM Mar 2026$6.57M -6016.2%—5.3%
MCRBSeres Therapeutics, Inc.LTM Mar 2026$2.53M +162.9%—220.4%
IRDOpus Genetics, Inc.LTM Mar 2026$2.04M +224.6%—17.0%
SEERSeer, Inc.LTM Mar 2026$1.1M +37.9%—7.3%
SPROSpero Therapeutics, Inc.LTM Mar 2026$624K -85.7%+25.5%1.1%
INOInovio Pharmaceuticals, Inc.LTM Mar 2026$331.65K -73.3%——
ENTXEntera Bio Ltd.LTM Mar 2026$133.03K +205.6%——
ANIXAnixa Biosciences, Inc.LTM Apr 2026$56K -125.7%——
HURATuHURA Biosciences, Inc.LTM Mar 2026$0 ———
ABOSAcumen Pharmaceuticals, Inc.LTM Mar 2026$0 ———
Peer median (excluding ENTX) $331.65K-73.3%+25.5%7.3%

Competitors are the stored peer set for ENTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(12.19M)(13.07M)(8.89M)(9.54M)(11.44M)
Depreciation & Amortization53K64K56K46K30K
Deferred Income Tax(217K)174K29K14K0
Stock-Based Compensation1.86M2.25M1.69M2.56M2.75M
Change in Working Capital1.41M(1.84M)(195K)112K1.26M
Accounts Receivables72K(63K)246K(126K)126K
Inventory(72K)0000
Accounts Payables74K(149K)66K49K316K
Other Working Capital1.34M(1.62M)(507K)189K815K
Other Non-Cash Items18K(78K)1.69M(5K)32K
Operating Cash Flow(9.06M)(12.5M)(7.31M)(6.82M)(7.37M)
Capital Expenditures(17K)(47K)(17K)(3K)(107K)
Acquisitions (Net)00000
Purchases of Investments00000
Sales of Investments00000
Other Investing Activities0(55K)000
Investing Cash Flow(17K)(102K)(17K)(3K)(107K)
Debt Repayment00000
Common Stock Issued21.81M13K6.62M3.96M13.71M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities3.58M0(580K)516K0
Financing Cash Flow25.38M13K6.04M4.48M13.71M
Effect of Forex Changes05K00(10K)
Net Change in Cash16.3M(12.58M)(1.29M)(2.35M)6.23M
Free Cash Flow(9.08M)(12.55M)(7.33M)(6.82M)(7.48M)

Entera Bio Ltd.

NASDAQ:ENTX

Intrinsic Alpha fair value

Locked

Current Price

$3.26

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.